Company news
Lexaria Bioscience Corp. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Lexaria's Investigational New Drug Application Filing Update
December 6, 2023
Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Studies of Proprietary Platform in Multibillion-Dollar GLP-1 Drug Space
October 31, 2023
Lexaria Enters New Global Exclusive Collaboration and License Agreement with SulfoSyn
October 12, 2023
Lexaria Granted Two New Patents in Canada
October 11, 2023
Lexaria Announces Pricing of $1.6 Million Registered Direct Offering
September 28, 2023
Lexaria to Evaluate Impact of DehydraTECH on Oral Performance of GLP-1 drugs used in products such as Ozempic, Wegovy and Rybelsus, Alone or Together with DehydraTECH-CBD
September 20, 2023
Lexaria Provides Update on Investigational New Drug Application Progress
August 29, 2023
Lexaria’s Plans to Study Weight Loss and Diabetes Control in a Human Clinical Study with DehydraTECH-CBD
August 1, 2023
Lexaria Incorporates New Subsidiary for CPG Products and Updates Human Nicotine Study
July 27, 2023
Lexaria Granted Strategically Important New US Patent For DehydraTECH-Nicotine Including Oral Pouch Products
July 18, 2023
Lexaria Receives New Patents
June 19, 2023
Lexaria’s DehydraTECH-CBD Lowers Blood Glucose Levels in Diabetes Animal Study
June 15, 2023
Lexaria Appoints New Chief Financial Officer
June 11, 2023
Lexaria Discovers that DehydraTECH-CBD Treatment in Hypertension Study HYPER-H21-4 Resulted in Reduction in Pro-Inflammatory Biomarkers
May 22, 2023
Lexaria's Hormone Study Shows Significant Enhancement in Oral Estradiol Delivery
May 17, 2023
Lexaria Bioscience Announces Closing of $2.0 Million Public Offering
May 10, 2023
Lexaria Announces 2023 Annual Meeting Results
May 9, 2023
Lexaria’s Human Clinical Nicotine Study Completes Dosing as Planned
May 7, 2023
Lexaria Bioscience Announces Pricing of $2.0 Million Public Offering
May 7, 2023
Lexaria Awards CRO Contract for Upcoming U.S. Phase 1b Hypertension Study
April 23, 2023
Lexaria is Receiving Four New Patents
April 19, 2023
Lexaria Discovers Potential Novel Mechanism From Hypertension Study HYPER-H21-4
February 20, 2023
Lexaria Receives First Granted Patent in Canada
December 28, 2022
Lexaria's DehydraTECH-CBD Achieves Superior Human Blood Absorption Levels
December 20, 2022
Lexaria’s Human Oral Nicotine Study Begins Dosing
December 19, 2022
Lexaria’s DehydraTECH-CBD(TM) Enhances Performance Compared to Epidiolex(R) in Seizure Study Program
November 28, 2022
Lexaria Bioscience Turns Focus to Dementia and Diabetes with New Studies
November 20, 2022
Lexaria Starts Study Evaluating the Effect of DehydraTECH-CBD on Diabetes
November 7, 2022
Lexaria Receives Independent Review Board Approval for its Upcoming Human Oral Nicotine Study
October 31, 2022
Lexaria's Human Clinical Hypertension Study a Success
October 26, 2022
Lexaria Welcomes Dr. Catherine Turkel to its Board of Directors
September 1, 2022
Lexaria Receives New Patent in Mexico
August 30, 2022
Lexaria Announces Positive Feedback from Pre-IND Meeting with FDA on DehydraTECH-CBD for Hypertension
August 9, 2022
Lexaria's DehydraTECH-CBD Hypertension Study HYPER-H21-4 Dosing Complete with No Serious Adverse Events
July 26, 2022
Lexaria's Licensee Premier Wellness Science Co., Ltd. Launches New Brand in Preparation to Deploy DehydraTECH CBD Products in Japan
July 25, 2022
Lexaria To Receive Third Patent Granted in Japan; Submits FDA Filing
July 13, 2022
Lexaria's Human Nicotine Study Nearing Start Date
July 12, 2022
Lexaria Signs Manufacturing and License Agreements with BevNology
June 20, 2022
Lexaria Grants License to AnodGen Bioceuticals
June 7, 2022
Lexaria Files Pre-IND Meeting Request Letter with U.S. FDA
June 5, 2022
Lexaria Grants Exclusive License to Premier Wellness Science Co., Ltd. for Strategic and Long-Term Partnership in the Japanese Market
June 2, 2022
Lexaria Grants License to Valcon Medical for the European Market
June 1, 2022
Lexaria Announces 2022 Annual Meeting Results
May 31, 2022
Lexaria Granted Patent for Use of DehydraTECH to Deliver Antiviral Drugs
April 20, 2022
Lexaria Commences Multi-Week Human Clinical Hypertension Study
April 18, 2022
Lexaria's Pulmonary Hypertension Clinical Study HYPER-H21-3 Delivers Positive Results
April 13, 2022
Lexaria Provides Update on Human Nicotine Study NIC-H22-1
April 11, 2022
Lexaria Begins New Nicotine Formulation Creation and Evaluation Program
April 10, 2022
Lexaria Begins DehydraTECH-CBD Epilepsy Research Program
March 14, 2022
Lexaria Granted Important New Oral Nicotine Patent
March 7, 2022
Decks
- Investor Presentation (December 2020)
Investor deck · 30 slides · Dec 31, 2020
- Investor Presentation (July 2019)
Investor deck · 27 slides · July 2019
- Investor Presentation (November 2017)
Investor deck · 16 slides · Nov 2, 2017